José F. Cardona

Statistics

Publications

Citations

653

H-Index

Active since

2019

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

Clinical Research Institute

Moderna Therapeutics (United States)

National Heart Centre Singapore

University of Alberta

José F. Cardona is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in vaccination, infectious diseases, and veterinary medicine.

Publications per year

2019–2025

Publications

Once-Daily Netarsudil Versus Twice-Daily Timolol in Patients With Elevated Intraocular Pressure: The Randomized Phase 3 ROCKET-4 Study

Albert S Khouri, Janet B. Serle, Jason Bacharach et al. · American Journal of Ophthalmology · 2019 · 105 citations

Pharmacy, Ophthalmology, Pharmacotherapy +17

A phase 3 trial of safety, tolerability, and immunogenicity of V114, 15-valent pneumococcal conjugate vaccine, compared with 13-valent pneumococcal conjugate vaccine in adults 50 years of age and older (PNEU-AGE)

Heather Platt, José F. Cardona, Miwa Haranaka et al. · Vaccine · 2021 · 91 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +17

Clinical Outcomes and Response to Vericiguat According to Index Heart Failure Event

Carolyn S.P. Lam, Anna Giczewska, Karen Sliwa et al. · JAMA Cardiology · 2020 · 82 citations · Full text

Medicine, Cardiology, Pharmacotherapy +13

Safety, tolerability, and immunogenicity of a 21-valent pneumococcal conjugate vaccine, V116, in healthy adults: phase 1/2, randomised, double-blind, active comparator-controlled, multicentre, US-based trial

Heather Platt, Tosin Omole, José F. Cardona et al. · The Lancet Infectious Diseases · 2022 · 82 citations

Veterinary Medicine, Immunology, Infectious Diseases +15

Lorundrostat in Participants With Uncontrolled Hypertension and Treatment-Resistant Hypertension

Manish Saxena, Luke J. Laffin, Claudio Borghi et al. · JAMA · 2025 · 68 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +16

1–5 of 11